Days after UCB reported the failure of its Novartis-partnered program, Roche has shared details of its own flop while clinging onto signs of clinical benefit that could still save the candidate.
Plus, the hole in the middle means it can be used simultaneously with penetration and during partnered sex. Talk about hitting all the right spots. This was a particularly exciting revelation for a ...
For the second time this week, a Big Pharma–partnered Parkinson’s disease asset has failed in the clinic. This time it’s Roche reporting that a drug under development with Prothena since 2013 was ...